Jessica Reuben

Vice President

48 South Service Road, Suite 400, Melville, NY 11747
745 5th Ave, Suite 500, New York, NY 10151
Jessica Reuben

About Me

As Vice President of PlanMedicare, Jessica is responsible for overseeing and executing high-level business development for the company. With over 15 years of experience working with digital start-ups, she has the background and knowledge to grow the PlanMedicare brand and network. Jessica graduated Magna Cum Laude from Lehigh University and currently lives in Manhattan.

Locations and Appointments

48 South Service Road,Suite 400
Melville, NY 11747
516-900-7877 Schedule an Appointment
745 5th Ave,Suite 500
New York, NY 10151
516-900-7877 Schedule an Appointment

Latest Blogs

An Overview of 2025 Medicare Advantage Plans

An Overview of 2025 Medicare Advantage Plans

As the Centers for Medicare and Medicaid Services (CMS) unveils.

A Preview of the 2025 Medicare Part D Prescription Drug Plans

A Preview of the 2025 Medicare Part D Prescription Drug Plans

The newly released 2025 stand-alone Medicare Part D prescription drug.

Jessica Reuben

Jessica Reuben

Vice President

As Vice President of PlanMedicare, Jessica is responsible for overseeing and executing high-level business development for the company. With over 15 years of experience working with digital start-ups, she has the background and knowledge to grow the PlanMedicare brand and network. Jessica graduated Magna Cum Laude from Lehigh University and currently lives in Manhattan.

Location:

48 South Service Road,Suite 400
Melville, NY 11747

Phone Number:

516-900-7877 Schedule an Appointment

Location:

745 5th Ave,Suite 500
New York, NY 10151

Phone Number:

516-900-7877 Schedule an Appointment

Latest Blogs

An Overview of 2025 Medicare Advantage Plans

An Overview of 2025 Medicare Advantage Plans

As the Centers for Medicare and Medicaid Services (CMS) unveils.

A Preview of the 2025 Medicare Part D Prescription Drug Plans

A Preview of the 2025 Medicare Part D Prescription Drug Plans

The newly released 2025 stand-alone Medicare Part D prescription drug.